Phase I trial of vorinostat combined with bevacizumab and CPT-11 in recurrent glioblastoma

Neuro-Oncology

Volumn 14, Issue 1, 2012, Pages 93-100

  Chinnaiyan, Prakash ^a   Chowdhary, Sajeel ^b   Potthast, Lisa ^a   Prabhu, Antony ^a   Tsai, Ya Yu ^a   Sarcar, Bhaswati ^a   Kahali, Soumen ^a   Brem, Steven ^a   Yu, H Michael ^a   Rojiani, Amyn ^c   Murtagh, Ryan ^a   Pan, Edward ^a  

^a H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

^b FLORIDA HOSPITAL CANCER INSTITUTE   (United States)

^c MEDICAL COLLEGE OF GEORGIA   (United States)

Author keywords

Bevacizumab; CPT 11; Recurrent glioblastoma; Vorinostat

Indexed keywords

BEVACIZUMAB; IRINOTECAN; PLATELET DERIVED GROWTH FACTOR AA; SOMATOMEDIN BINDING PROTEIN 5; TEMOZOLOMIDE; VORINOSTAT;

ADULT; AGED; ARTICLE; BLOOD SAMPLING; BRAIN ISCHEMIA; CLINICAL ARTICLE; CONTROLLED STUDY; DIARRHEA; DRUG DOSE ESCALATION; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG MEGADOSE; DRUG TOLERABILITY; DRUG WITHDRAWAL; FATIGUE; FEMALE; GLIOBLASTOMA; HUMAN; HYPERTENSION; HYPOTENSION; ISCHEMIA; LOW DRUG DOSE; MALE; MAXIMUM TOLERATED DOSE; MUCOSA INFLAMMATION; MULTIPLE CYCLE TREATMENT; NAUSEA; OVERALL SURVIVAL; PHASE 1 CLINICAL TRIAL; PLASMA; PROGRESSION FREE SURVIVAL; PROTEOMICS; RECURRENT CANCER; RECURRENT DISEASE; SENSORY NEUROPATHY; STOMACH PAIN; VOMITING;

ADULT; AGED; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BRAIN NEOPLASMS; CAMPTOTHECIN; DISEASE-FREE SURVIVAL; FEMALE; GLIOBLASTOMA; HUMANS; HYDROXAMIC ACIDS; INSULIN-LIKE GROWTH FACTOR BINDING PROTEIN 5; MALE; MAXIMUM TOLERATED DOSE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; PLATELET-DERIVED GROWTH FACTOR; PROTEOMICS;

EID: 84856238982     PISSN: 15228517     EISSN: 15235866     Source Type: Journal    
DOI: 10.1093/neuonc/nor187     Document Type: Article

References (37)

1. Wen PY, Kesari S. Malignant gliomas in adults. The New England Journal of Medicine. 2008;359(5):492-507.
2. Stupp R, Mason WP, van den Bent MJ, et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. The New England Journal of Medicine. 2005;352(10): 987-996. (Pubitemid 40349501)
3. Wong ET, Hess KR, Gleason MJ, et al. Outcomes and prognostic factors in recurrent glioma patients enrolled onto phase II clinical trials. J Clin Oncol. 1999;17(8):2572-2578. (Pubitemid 29368260)
4. Friedman HS, Prados MD, Wen PY, et al. Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma. J Clin Oncol. 2009;27(28):4733-4740.
5. Vredenburgh JJ, Desjardins A, Herndon JE, 2nd, et al. Bevacizumab plus irinotecan in recurrent glioblastoma multiforme. J Clin Oncol. 2007;25(30):4722-4729. (Pubitemid 350086473)
6. Kreisl TN, Kim L, Moore K, et al. Phase II trial of single-agent bevacizumab followed by bevacizumab plus irinotecan at tumor progression in recurrent glioblastoma. J Clin Oncol. 2009;27(5):740-745.
7. Norden AD, Drappatz J, Muzikansky A, et al. An exploratory survival analysis of anti-angiogenic therapy for recurrent malignant glioma. Journal of Neuro-oncology. 2009;92(2):149-155.
8. Norden AD, Drappatz J, Wen PY. Antiangiogenic therapies for highgrade glioma. Nat Rev Neurol. 2009;5(11):610-620.
9. Duvic M, Talpur R, Ni X, et al. Phase 2 trial of oral vorinostat (suberoylanilide hydroxamic acid, SAHA) for refractory cutaneous T-cell lymphoma (CTCL). Blood. 2007;109(1):31-39. (Pubitemid 46053039)
10. Galanis E, Jaeckle KA, Maurer MJ, et al. Phase II trial of vorinostat in recurrent glioblastoma multiforme: A north central cancer treatment group study. J Clin Oncol. 2009;27(12):2052-2058.
11. Qian DZ, Kato Y, Shabbeer S, et al. Targeting tumor angiogenesis with histone deacetylase inhibitors: The hydroxamic acid derivative LBH589. Clin Cancer Res. 2006;12(2):634-642. (Pubitemid 43166159)
12. Qian DZ, Wang X, Kachhap SK, et al. The histone deacetylase inhibitor NVP-LAQ824 inhibits angiogenesis and has a greater antitumor effect in combination with the vascular endothelial growth factor receptor tyrosine kinase inhibitor PTK787/ZK222584. Cancer Research. 2004;64(18):6626-6634. (Pubitemid 39297923)
13. Bevins RL, Zimmer SG. It's about time: Scheduling alters effect of histone deacetylase inhibitors on camptothecin-treated cells. Cancer Research. 2005;65(15):6957-6966. (Pubitemid 41060736)
14. Marchion DC, Bicaku E, Daud AI, Sullivan DM, Munster PN. Valproic acid alters chromatin structure by regulation of chromatin modulation proteins. Cancer Research. 2005;65(9):3815-3822. (Pubitemid 40616361)
15. MarchionDC, Bicaku E,DaudAI, SullivanDM,Munster PN. In vivosynergy between topoisomerase II and histone deacetylase inhibitors: Predictive correlates. Molecular Cancer Therapeutics. 2005;4(12):1993-2000. (Pubitemid 43056982)
16. Sarcar B, Kahali S, Chinnaiyan P. Vorinostat enhances the cytotoxic effects of the topoisomerase I inhibitor SN38 in glioblastoma cell lines. Journal of Neuro-oncology. 2010;99(2):201-207.
17. Calabrese C, Poppleton H, Kocak M, et al. A perivascular niche for brain tumor stem cells. Cancer Cell. 2007;11(1):69-82. (Pubitemid 46054518)
18. Dunlap SM, Celestino J, Wang H, et al. Insulin-like growth factor binding protein 2 promotes glioma development and progression. Proceedings of the National Academy of Sciences of the United States of America. 2007;104(28):11736-11741. (Pubitemid 47175082)
19. Mehrian-Shai R, Chen CD, Shi T, et al. Insulin growth factor-binding protein 2 is a candidate biomarker for PTEN status and PI3K/Akt pathway activation in glioblastoma and prostate cancer. Proceedings of the National Academy of Sciences of the United States of America. 2007;104(13):5563-5568. (Pubitemid 47175720)
20. Moore LM, Holmes KM, Smith SM, et al. IGFBP2 is a candidate biomarker for Ink4a-Arf status and a therapeutic target for high-grade gliomas. Proceedings of the National Academy of Sciences of the United States of America. 2009;106(39):16675-16679.
21. Santosh V, Arivazhagan A, Sreekanthreddy P, et al. Grade-specific expression of insulin-like growth factor-binding proteins-2, -3, and -5 in astrocytomas: IGFBP-3 emerges as a strong predictor of survival in patients with newly diagnosed glioblastoma. Cancer Epidemiol Biomarkers Prev. 2010;19(6):1399-1408.
22. Soroceanu L, Kharbanda S, Chen R, et al. Identification of IGF2 signaling through phosphoinositide-3-kinase regulatory subunit 3 as a growth-promoting axis in glioblastoma. Proceedings of the National Academy of Sciences of the United States of America. 2007;104(9):3466-3471. (Pubitemid 46364182)
23. Wang H, Wang H, Shen W, et al. Insulin-like growth factor binding protein 2 enhances glioblastoma invasion by activating invasion-enhancing genes. Cancer Research. 2003;63(15): 4315-4321. (Pubitemid 36950996)
24. Lin Y, Jiang T, Zhou K, et al. Plasma IGFBP-2 levels predict clinical outcomes of patients with high-grade gliomas. Neuro-oncology. 2009;11(5):468-476.
25. Sreekanthreddy P, Srinivasan H, Kumar DM, et al. Identification of potential serum biomarkers of glioblastoma: Serum osteopontin levels correlate with poor prognosis. Cancer Epidemiol Biomarkers Prev. 2010;19(6):1409-1422.
26. Shariat SF, Lamb DJ, Kattan MW, et al. Association of preoperative plasma levels of insulin-like growth factor I and insulinlike growth factor binding proteins-2 and -3 with prostate cancer invasion, progression, and metastasis. J Clin Oncol. 2002;20(3): 833-841. (Pubitemid 34111393)
27. Ahn BY, Elwi AN, Lee B, et al. Genetic screen identifies insulin-like growth factor binding protein 5 as a modulator of tamoxifen resistance in breast cancer. Cancer Research. 2010;70(8): 3013-3019.
28. Walker G, MacLeod K, Williams AR, Cameron DA, Smyth JF, Langdon SP. Insulin-like growth factor binding proteins IGFBP3, IGFBP4, and IGFBP5 predict endocrine responsiveness in patients with ovarian cancer. Clin Cancer Res. 2007;13(5):1438-1444. (Pubitemid 46450433)
29. Rho SB, Dong SM, Kang S, et al. Insulin-like growth factor-binding protein-5 (IGFBP-5) acts as a tumor suppressor by inhibiting angiogenesis. Carcinogenesis. 2008;29(11):2106-2111.
30. Dunn IF, Heese O, Black PM. Growth factors in glioma angiogenesis: FGFs, PDGF, EGF, and TGFs. Journal of Neuro-oncology. 2000;50(1- 2):121-137. (Pubitemid 32169649)
31. Shih AH, Dai C, Hu X, Rosenblum MK, Koutcher JA, Holland EC. Dose-dependent effects of platelet-derived growth factor-B on glial tumorigenesis. Cancer Research. 2004;64(14):4783-4789. (Pubitemid 38924521)
32. Yu J, Ustach C, Kim HR. Platelet-derived growth factor signaling and human cancer. Journal of Biochemistry and Molecular Biology. 2003;36(1):49-59. (Pubitemid 36836256)
33. Crawford Y, Kasman I, Yu L, et al. PDGF-C mediates the angiogenic and tumorigenic properties of fibroblasts associated with tumors refractory to anti-VEGF treatment. Cancer Cell. 2009;15(1):21-34.
34. Dong J, Grunstein J, Tejada M, et al. VEGF-null cells require PDGFR alpha signaling-mediated stromal fibroblast recruitment for tumorigenesis. The EMBO Journal. 2004;23(14):2800-2810. (Pubitemid 39013552)
35. Greenberg JI, Shields DJ, Barillas SG, et al. A role for VEGF as a negative regulator of pericyte function and vessel maturation. Nature. 2008;456(7223):809-813.
36. Shikada Y, Yonemitsu Y, Koga T, et al. Platelet-derived growth factor-AA is an essential and autocrine regulator of vascular endothelial growth factor expression in non-small cell lung carcinomas. Cancer Research. 2005;65(16):7241-7248. (Pubitemid 41161255)
37. Faraone D, Aguzzi MS, Toietta G, et al. Platelet-derived growth factorreceptor alpha strongly inhibits melanoma growth in vitro and in vivo. Neoplasia. 2009;11(8):732-742.